DDInter1101 DDInter1752
Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lum
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Lumacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enfortumab vedotin
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meloxicam
Lumacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enasidenib
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Tolvaptan
Lumacaftor {u} may lead to a major life threatening interaction when taken with {v} Capmatinib
Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Lumacaftor may lead to a major life threatening interaction when taken with Tolvaptan
Lumacaftor may lead to a major life threatening interaction when taken with Capmatinib